We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Show more
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update PR Newswire LAUSANNE, Switzerland, Nov. 7, 2024 LOTIS-5 full enrollment and LOTIS-7...
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting PR Newswire LAUSANNE, Switzerland, Nov. 5, 2024 Oral presentation of...
ADC Therapeutics to Present at November Investor Conferences PR Newswire LAUSANNE, Switzerland, Nov. 4, 2024 LAUSANNE, Switzerland, Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Nov. 1, 2024 LAUSANNE, Switzerland, Nov. 1, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:...
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 PR Newswire LAUSANNE, Switzerland, Oct. 31, 2024 LAUSANNE, Switzerland, Oct. 31, 2024...
LAUSANNE, Switzerland, Oct. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.18 | 6.22837370242 | 2.89 | 3.3 | 2.8119 | 443678 | 3.06344611 | CS |
4 | 0.34 | 12.4542124542 | 2.73 | 3.3 | 2.7 | 376848 | 3.03835684 | CS |
12 | 0.135 | 4.5996592845 | 2.935 | 3.45 | 2.61 | 352226 | 3.03050965 | CS |
26 | -1.64 | -34.8195329087 | 4.71 | 4.83 | 2.4505 | 548703 | 3.25796896 | CS |
52 | 2.335 | 317.68707483 | 0.735 | 6.04 | 0.359908 | 643682 | 3.17100484 | CS |
156 | -26.41 | -89.5861601085 | 29.48 | 29.74 | 0.359908 | 478149 | 4.13981736 | CS |
260 | -26.93 | -89.7666666667 | 30 | 56.5899 | 0.359908 | 404758 | 9.64195898 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions